Key Insights

Highlights

Success Rate

88% trial completion (above average)

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 40/100

Termination Rate

6.9%

2 terminated out of 29 trials

Success Rate

88.2%

+1.7% vs benchmark

Late-Stage Pipeline

24%

7 trials in Phase 3/4

Results Transparency

33%

5 of 15 completed with results

Key Signals

5 with results88% success

Data Visualizations

Phase Distribution

23Total
Not Applicable (14)
P 2 (2)
P 3 (4)
P 4 (3)

Trial Status

Completed15
Recruiting4
Unknown4
Terminated2
Active Not Recruiting2
Enrolling By Invitation1

Trial Success Rate

88.2%

Benchmark: 86.5%

Based on 15 completed trials

Clinical Trials (29)

Showing 20 of 20 trials
NCT04193709Not ApplicableCompletedPrimary

Recovery of Bladder and Sexual Function After Human Spinal Cord Injury

NCT05380661Not ApplicableCompleted

Heart Rate Variability and Anxiety During Urinary Bladder Catheterization

NCT07387315Phase 4Not Yet Recruiting

A Randomized, Placebo-controlled Trial of Nitrous Oxide During In-office Bladder Botox Injections

NCT05141487Recruiting

Feasibility of Triggered Sacral Neuromodulation for Neurogenic Bladder

NCT03245242Active Not Recruiting

Pediatric Urology Recovery After Surgery Endeavor (PURSUE)

NCT04128709Not ApplicableRecruitingPrimary

Measurement of Bladder Pressure With a Novel External Device (Cystomanometer) - Home Use

NCT05232253Not ApplicableActive Not RecruitingPrimary

Cystoealstometer (Bladder Monitor Device)-Home Use

NCT06978205Not ApplicableRecruiting

Effect of Urethral Balloon Dilatation on Urinary Retention After Spinal Cord Injury

NCT06336304Recruiting

NXT Post-Market Clinical Follow-up

NCT03456089Not ApplicableEnrolling By InvitationPrimary

Measurement of Bladder Pressure With a Novel External Device, Comparison to Urodynamics Testing

NCT05740527Not ApplicableCompletedPrimary

Ambulatory Closed-loop Stimulation for Bladder Control

NCT04819360Phase 4TerminatedPrimary

Botulinum Toxin a Vs Anticholinergic Treatment of Neurogenic Overactive Bladder in Patients with Multiple Sclerosis

NCT06445426Completed

Cystometry Using a Novel Microsensor System in Patients With Neurogenic Bladder Dysfunction

NCT05075642Unknown

Multicenter Observational Study for the Evaluation in Clinical Practice of Urinary Disorders in Multiple Sclerosis

NCT04528784Not ApplicableCompleted

Feasibility Study of Transcutaneous Tibial Nerve Stimulation for Urinary Symptoms in People With Multiple Sclerosis

NCT01557244Phase 3CompletedPrimary

A Study To Find Out How Fesoterodine Works In Children Aged 6 To 17 Years With Bladder Overactivity Caused By A Neurological Condition

NCT02501928Phase 3CompletedPrimary

Open-label Long-term Extension Study of Fesoterodine in Japanese Subjects With Neurogenic Detrusor Overactivity.

NCT02582151Not ApplicableCompletedPrimary

Transcutaneous Peripheral Neuromodulation for Neurogenic Bladder

NCT03187795Phase 2Unknown

Mirabegron and Oxybutynin Safety and Efficacy Trial in Spinal Cord Injury

NCT02044510Phase 2TerminatedPrimary

Urodynamic and Clinical Efficacy of Mirabegron for Neurogenic Bladder Patients

Scroll to load more

Research Network

Activity Timeline